Skip to main content
NCBI home page
Bulletin of the New York Academy of Medicine logoLink to Bulletin of the New York Academy of Medicine
. 1989 Jan;65(1):16–25.

Modulation of in vitro antitumor immunity in response to the biological activators interleukin-2, gamma interferon, and granulocyte monocyte-colony stimulating factor in the peripheral blood of cancer patients receiving cytotoxic chemotherapy.

J E Harris, D P Braun
PMCID: PMC1807780  PMID: 2513993

Full text

PDF
16

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Sarraf M., Wong P., Sardesai S., Vaitkevicius V. K. Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs. Cancer. 1970 Aug;26(2):262–268. doi: 10.1002/1097-0142(197008)26:2<262::aid-cncr2820260204>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Borella L., Webster R. G. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res. 1971 Apr;31(4):420–426. [PubMed] [Google Scholar]
  3. Braum D. P., Harris J. E., Rubenstein M. Relationship of arachidonic acid metabolism to indomethacin-sensitive immunoregulatory function and lymphocyte PGE sensitivity in peripheral blood mononuclear cells of disseminated solid tumor cancer patients. J Immunopharmacol. 1984;6(3):227–236. doi: 10.3109/08923978409019463. [DOI] [PubMed] [Google Scholar]
  4. Braun D. P., Bonomi P. D., Taylor S. G., 4th, Harris J. E. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group. J Biol Response Mod. 1987 Jun;6(3):331–345. [PubMed] [Google Scholar]
  5. Braun D. P., Cobleigh M. A., Harris J. E. Multiple concurrent immunoregulatory defects in cancer patients with depressed PHA-induced lymphocyte DNA synthesis. Clin Immunol Immunopathol. 1980 Sep;17(1):89–101. doi: 10.1016/0090-1229(80)90076-8. [DOI] [PubMed] [Google Scholar]
  6. Braun D. P., Harris J. E. Abnormal indomethacin-sensitive suppression in peripheral blood mononuclear cells of cancer patients restricts augmentation by interleukin-2. J Biol Response Mod. 1984 Oct;3(5):533–540. [PubMed] [Google Scholar]
  7. Braun D. P., Harris J. E. Effect of combination chemotherapy on PGE-mediated immunoregulation in the peripheral blood mononuclear cells of solid tumor cancer patients. J Biol Response Mod. 1984 Aug;3(4):391–396. [PubMed] [Google Scholar]
  8. Braun D. P., Harris J. E. Relationship of leukocyte numbers, immunoregulatory cell function, and phytohemagglutinin responsiveness in cancer patients. J Natl Cancer Inst. 1981 Oct;67(4):809–814. [PubMed] [Google Scholar]
  9. Hancock W. W., Pleau M. E., Kobzik L. Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E. J Immunol. 1988 May 1;140(9):3021–3025. [PubMed] [Google Scholar]
  10. Harris J., Sengar D., Stewart T., Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer. 1976 Feb;37(2 Suppl):1058–1069. doi: 10.1002/1097-0142(197602)37:2+<1058::aid-cncr2820370813>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  11. Hersh E. M., Patt Y. Z., Murphy S. G., Dicke K., Zander A., Adegbite M., Goldman R. Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res. 1980 Sep;40(9):3134–3140. [PubMed] [Google Scholar]
  12. Hersh E. M., Whitecar J. P., Jr, McCredie K. B., Bodey G. P., Sr, Freireich E. J. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med. 1971 Nov;285(22):1211–1216. doi: 10.1056/NEJM197111252852201. [DOI] [PubMed] [Google Scholar]
  13. Hirschberg T., Randazzo B., Hirschberg H. Effects of methylprednisolone on the in vitro induction and function of suppressor cells in man. Scand J Immunol. 1980;12(1):33–39. doi: 10.1111/j.1365-3083.1980.tb00038.x. [DOI] [PubMed] [Google Scholar]
  14. Knudsen P. J., Dinarello C. A., Strom T. B. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol. 1986 Nov 15;137(10):3189–3194. [PubMed] [Google Scholar]
  15. Kunkel S. L., Spengler M., May M. A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988 Apr 15;263(11):5380–5384. [PubMed] [Google Scholar]
  16. Mavligit G. M., Raphael L. S., Calvo D. B., 3rd, Wong W. L. Indomethacin-induced, monocyte-dependent restoration of local graft-versus-host reaction among cells from cancer patients. J Natl Cancer Inst. 1980 Aug;65(2):317–320. [PubMed] [Google Scholar]
  17. Spina C. A., Dorey F., Vescera C., Brosman S., Fahey J. L. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients. Cancer Res. 1981 Nov;41(11 Pt 1):4324–4330. [PubMed] [Google Scholar]
  18. Von Roenn J., Harris J. E., Braun D. P. Suppressor cell function in solid tumor cancer patients. J Clin Oncol. 1987 Jan;5(1):150–159. doi: 10.1200/JCO.1987.5.1.150. [DOI] [PubMed] [Google Scholar]
  19. Vosixa G., Thies J. Effect of indomethacin on blastogenesis of lymphocytes from cancer patients: differentiation of patient types. Clin Immunol Immunopathol. 1979 May;13(1):30–38. doi: 10.1016/0090-1229(79)90017-5. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES